Coherus Biosciences, Inc. (CHRS): Peter K. Watler , Chief Technical Officer of Coherus Biosciences, Inc. sold 12,000 shares on May 17, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $20.00 per share for a total value of $240,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, Peter K. Watler (Chief Technical Officer) sold 21,493 shares at $23.70 per share price.On May 4, 2016, Alan C. Herman (Chief Scientific Officer) sold 4,250 shares at $19.38 per share price.Also, On Dec 2, 2015, Dennis M Lanfear (President and CEO) sold 400 shares at $31.75 per share price.On Nov 16, 2015, Christos Richards (director) sold 15,000 shares at $27.51 per share price.
Shares of Coherus Biosciences Inc (CHRS) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.53 points or -2.72% at $18.96 with 4,32,852 shares getting traded. Post opening the session at $19.27, the shares hit an intraday low of $17.981 and an intraday high of $19.3 and the price vacillated in this range throughout the day. The company has a market cap of $742,132 M and the number of outstanding shares has been calculated to be 39,14,20,00,000 shares. The 52-week high of Coherus Biosciences Inc is $38.1 and the 52-week low is $12.04.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.